http://orcid.org/0000-0002-0981-0486
References
- World Health Organization. Chronic respiratory disease: asthma. Available from: http://www.who.int/respiratory/asthma/scope/en/ [last accessed July 2017].
- de Groot JC, ten Brinke A, Bel EHD. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res 2015;1:00024–2015.
- Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy 2014;7:53–65.
- Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJM, Bel EH, Sterk PJ, et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115–120.
- Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2015;136:825–826.
- Bacci E, Cianchetti S, Ruocco L, Bartoli ML, Carnevali S, Dente FL, Di Franco A, et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin Exp Allergy 1998;28:1237–1243.
- Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med 2014;9:187–192.
- Rowe BH, Spooner C, Ducharme F, Bretzlaff J, Bota G. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001;1:CD002178
- Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-management-and-prevention/ [last accessed 13 Jul 2017].
- Lefebvre P, Duh MS, Lafeuille M-H, Gozalo L, Desai U, Robitaille M-N, Albers F, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin 2017;33:57–65.
- Lassalle P, Sergant M, Delneste Y, Cosset P, Wallaert B, Zandecki M, Capron A, et al. Levels of soluble IL-2 receptor in plasma from asthmatics. Correlations with blood eosinophilia, lung function, and corticosteroid therapy. Clin Exper Immunol 2008;87:266–271.
- Sakae TM, Maurici R, Trevisol DJ, Pizzichini MM, Pizzichini E. Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis. J Bras Pneumol 2014;40:552–563.
- Prazma CM, Bel EH, Barnes NC, Price R, Albers FC, Yancey SW. Steroid sparing response with mepolizumab: durability of steroid reduction in severe asthma. J Allergy Clin Immunol 2016;137:AB16.
- Casciano J, Krishnan JA, Small MB, Buck PO, Gopalan G, Li C, Kemp R, Dotiwala Z. Burden of asthma with elevated blood eosinophil levels. BMC Pulm Med 2016;16:100.
- Baigelman W, Chodosh S, Pizzuto D, Cupples LA. Sputum and blood eosinophils during corticosteroid treatment of acute exacerbations of asthma. Am J Med 1983;75:929–936.
- Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189–1197.
- Prazma CBE, Price R, Bradford E, Albers FC, Yancey S. Oral corticosteroid dose modulation in severe asthma: impact on peripheral blood eosinophil count. Am J Resp Crit Care Med 2017:A1363.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651–659.
- Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H. Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Thorax 2014;69:1141–1142.
- Ortega H, Gleich G, Mayer B, Yancey S. Reproducibility of a single blood eosinophil measurement as a biomarker in severe eosinophilic asthma. Ann Am Thorac Soc 2015;12:1896–1897.
- Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, Field SK, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA 2017;317:269–279.